Author:
Niba Peter Thelma Ngwa,Nji Akindeh M.,Evehe Marie-Solange,Ali Innocent M.,Netongo Palmer Masumbe,Ngwafor Randolph,Moyeh Marcel N.,Ngum Lesley Ngum,Ndum Oliva Ebie,Acho Fon Abongwa,Mbu’u Cyrille Mbanwi,Fosah Dorothy A.,Atogho-Tiedeu Barbara,Achonduh-Atijegbe Olivia,Djokam-Dadjeu Rosine,Chedjou Jean Paul Kengne,Bigoga Jude D.,Moukoko Carole Else Eboumbou,Ajua Anthony,Achidi Eric,Tallah Esther,Leke Rose G. F.,Tourgordi Alexis,Ringwald Pascal,Alifrangis Michael,Mbacham Wilfred F.
Abstract
Abstract
Background
Malaria remains highly endemic in Cameroon. The rapid emergence and spread of drug resistance was responsible for the change from monotherapies to artemisinin-based combinations. This systematic review and meta-analysis aimed to determine the prevalence and distribution of Plasmodium falciparum drug resistance markers within an evolving efficacy of anti-malarial drugs in Cameroon from January 1998 to August 2020.
Methods
The PRISMA-P and PRISMA statements were adopted in the inclusion of studies on single nucleotide polymorphisms (SNPs) of P. falciparum anti-malarial drug resistance genes (Pfcrt, Pfmdr1, Pfdhfr, Pfdhps, Pfatp6, Pfcytb and Pfk13). The heterogeneity of the included studies was evaluated using the Cochran’s Q and I2 statistics. The random effects model was used as standard in the determination of heterogeneity between studies.
Results
Out of the 902 records screened, 48 studies were included in this aggregated meta-analysis of molecular data. A total of 18,706 SNPs of the anti-malarial drug resistance genes were genotyped from 47,382 samples which yielded a pooled prevalence of 35.4% (95% CI 29.1–42.3%). Between 1998 and 2020, there was significant decline (P < 0.0001 for all) in key mutants including Pfcrt 76 T (79.9%-43.0%), Pfmdr1 86Y (82.7%-30.5%), Pfdhfr 51I (72.2%-66.9%), Pfdhfr 59R (76.5%-67.8%), Pfdhfr 108 N (80.8%-67.6%). The only exception was Pfdhps 437G which increased over time (30.4%-46.9%, P < 0.0001) and Pfdhps 540E that remained largely unchanged (0.0%-0.4%, P = 0.201). Exploring mutant haplotypes, the study observed a significant increase in the prevalence of Pfcrt CVIET mixed quintuple haplotype from 57.1% in 1998 to 57.9% in 2020 (P < 0.0001). In addition, within the same study period, there was no significant change in the triple Pfdhfr IRN mutant haplotype (66.2% to 67.3%, P = 0.427). The Pfk13 amino acid polymorphisms associated with artemisinin resistance were not detected.
Conclusions
This review reported an overall decline in the prevalence of P. falciparum gene mutations conferring resistance to 4-aminoquinolines and amino alcohols for a period over two decades. Resistance to artemisinins measured by the presence of SNPs in the Pfk13 gene does not seem to be a problem in Cameroon.
Systematic review registration PROSPERO CRD42020162620
Funder
DELTAS Africa/Wellcome trust
Publisher
Springer Science and Business Media LLC
Subject
Infectious Diseases,Parasitology
Reference113 articles.
1. WHO. World Malaria Report 2019. Geneva, World Health Organization. https://www.who.int/publications-detail/world-malaria-report-2019. Accessed on 8th December, 2019.
2. Cameroon National Malaria Control Programme (NMCP). Annual report of activities 2006, Yaoundé, 2006.
3. WHO. World Malaria Report 2008. Geneva, World Health Organization, 2008. http://www.who.int/malaria/publications/atoz/9789241563697/en/. Accessed on 10th August, 2017.
4. Sayang C, Gausseres M, Vernazza-Licht N, Malvy D, Bley D, Millet P. Treatment of malaria from monotherapy to artemisinin-based combination therapy by health professionals in urban health facilities in Yaoundé, central province Cameroon. Malar J. 2009;8:176.
5. Cameroon National Malaria Control Programme (NMCP). Annual report of activities 2016. Yaoundé, 2016.